Brief: Lipocine Says First Participant Dosed In Pilot Clinical Bridge Study Of Lpcn 1154
03/04/2023 12:25
April 3 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE INC: FIRST PARTICIPANT HAS BEEN DOSED IN A PILOT
CLINICAL BRIDGE STUDY OF LPCN 1154 AND APPROVED INJECTABLE
BREXANOLONE
* LIPOCINE INC - TOPLINE STUDY RESULTS EXPECTED IN H1 2023
Further company coverage: LPCN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy